Loss of imprinting contributes to overexpression of IGF2 in cancers of the prostate and colon and cancers with stem cell-like features25–28, while deregulation of IGF2 in cancers is also attributable to abnormal expression of transcription factors29–31. This evidence concerns the gene IGF2 and cancer.